What Is Tesamorelin?
Tesamorelin is a synthetic version of growth hormone-releasing hormone, usually shortened to GHRH. Natural GHRH is a peptide made in the hypothalamus, a small region of the brain. It tells the pituitary gland to release growth hormone in pulses. Tesamorelin is designed to send a similar message.
Tesamorelin is not growth hormone itself. It works one step earlier in the biological pathway by encouraging the pituitary gland to release more of the body's own growth hormone. This then increases insulin-like growth factor 1, better known as IGF-1, which helps carry out some of growth hormone's effects in tissues around the body.
Tesamorelin is the active ingredient in the prescription medicines EGRIFTA WR and EGRIFTA SV. In the United States, it is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss medicine, bodybuilding drug or anti-ageing treatment.
Is Tesamorelin a Peptide?
Yes. Tesamorelin is a peptide because its main structure is a chain of amino acids connected by peptide bonds.
The current EGRIFTA WR prescribing information describes tesamorelin as the 44-amino-acid sequence of human growth hormone-releasing factor with an added hexenoyl group. Growth hormone-releasing factor is another name for GHRH. The added chemical group is attached at the beginning of the molecule and distinguishes tesamorelin from the natural hormone sequence.
That modification does not stop tesamorelin from being a peptide. It makes it a modified synthetic peptide, built from the natural GHRH sequence but adjusted so that the signal can last longer than unmodified GHRH.
| Feature | Plain-English meaning |
|---|---|
| 44-amino-acid chain | The peptide backbone follows the full human GHRH sequence |
| Hexenoyl group | A small chemical addition at the start of the chain that changes the natural GHRH structure |
| GHRH analogue | A laboratory-made molecule designed to act like natural growth hormone-releasing hormone |
| Pituitary target | Its main signal is directed at cells in the pituitary gland that make growth hormone |
What Does Tesamorelin Do?
Tesamorelin binds to GHRH receptors on somatotroph cells in the pituitary gland. These are the cells responsible for making and releasing growth hormone.
The sequence can be pictured as a short signalling chain:
- Tesamorelin activates the GHRH receptor in the pituitary gland.
- The pituitary releases more of the body's own growth hormone in pulses.
- Growth hormone acts directly on some tissues and prompts the liver and other tissues to produce more IGF-1.
- Growth hormone and IGF-1 influence fat metabolism, body composition and several other biological processes.
This indirect route is the main point to remember. Tesamorelin does not replace growth hormone. It stimulates a working hypothalamic-pituitary system to produce a response. That is why the approved label lists disruption of this system, including some forms of pituitary disease, surgery, radiation or head injury, as a reason the medicine must not be used.
Growth hormone has both anabolic and lipolytic effects. Anabolic means it can support the building or maintenance of tissues. Lipolytic means it can help mobilise stored fat. Those words describe biological actions, not a promise that tesamorelin will produce muscle growth or general weight loss.
What Is Tesamorelin Used For?
The approved use of tesamorelin is narrow and specific. EGRIFTA WR is indicated for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
HIV-associated lipodystrophy is a group of changes in where the body stores fat. Some people living with HIV develop an increase in visceral adipose tissue, which is fat stored deep inside the abdomen around the internal organs. This can make the abdomen appear larger even when total body weight changes very little.
Visceral fat is different from the softer subcutaneous fat that sits just under the skin. This matters because the main clinical trials measured visceral fat with CT scans. They did not show that tesamorelin simply removes fat evenly from the whole body.
Tesamorelin also does not treat HIV itself. It is not an antiretroviral medicine, and its approval does not suggest that it controls the virus or replaces an HIV treatment plan.
The prescribing information is equally clear that EGRIFTA WR is not indicated for weight-loss management. In the pivotal studies, average body weight remained broadly stable even though visceral abdominal fat fell. Tesamorelin is therefore better understood as a medicine that can change fat distribution in a defined patient group, not as a conventional weight-loss drug.
Does Tesamorelin Work?
Tesamorelin has been tested in randomised, double-blind, placebo-controlled human trials. This places it in a much stronger evidence category than experimental compounds supported only by animal or laboratory studies.
The approved label summarises two main phase 3 studies involving adults with HIV, lipodystrophy and excess abdominal fat. After 26 weeks, mean visceral fat changed by about 18% below baseline in one tesamorelin group and 14% below baseline in the other. The corresponding placebo groups changed by about 2% above baseline and 2% below baseline.
The same studies found only small average changes in body weight. Waist circumference fell modestly, while lean body mass increased by about 1.2 to 1.3 kilograms on average. These are group averages from a specific clinical population. They do not predict what will happen to an individual, and they do not establish the same effects in healthy people.
The extension phases reveal another useful detail. People who continued tesamorelin generally maintained more of the visceral-fat reduction. In people who stopped tesamorelin and switched to placebo, visceral fat began to return. The effect therefore appears to depend on continued treatment rather than representing a permanent change after a short course.
A 2026 meta-analysis of five randomised trials reached a similar broad conclusion. It found reductions in visceral fat, trunk fat, liver fat and waist circumference, together with an increase in lean body mass, in people with HIV-associated lipodystrophy. It did not find a significant reduction in BMI or subcutaneous abdominal fat.
The evidence supports the approved use. It should not be stretched into proof for every online claim made about tesamorelin.
How Long Does Tesamorelin Take to Work?
The main clinical studies assessed changes over 26 weeks, with some participants followed for a further 26 weeks. That tells us when researchers measured meaningful group-level changes. It does not create a guaranteed personal timeline.
Some biological markers, including IGF-1, can change earlier than body composition. A change in a blood marker is not the same as a visible or clinically useful change in visceral fat. Response also varied between participants, which is why the prescribing information tells clinicians to consider the balance of benefit and risk if visceral fat is not reduced.
This page does not provide a treatment schedule. The appropriate product, monitoring plan and duration are medical decisions tied to the approved indication and an individual's health.
Is Tesamorelin a Weight-Loss Peptide?
Not in the way that phrase is usually used online. Tesamorelin is a peptide medicine that can reduce visceral abdominal fat in adults with HIV-associated lipodystrophy. The FDA-approved label specifically says it is not indicated for weight-loss management and describes its overall effect on body weight as neutral.
That can sound contradictory until fat distribution is separated from body weight. A person can lose some fat from deep inside the abdomen while their total weight changes very little. Lean tissue, fluid and fat in other areas all contribute to the number on a scale.
Evidence from the approved population cannot simply be transferred to people seeking general weight loss. The underlying condition, baseline fat distribution, other medicines and clinical monitoring all matter.
Does Tesamorelin Reduce Liver Fat?
There is promising human evidence, but liver-fat reduction is not the approved indication.
A small randomised study published in JAMA followed 50 adults with HIV and abdominal fat accumulation for six months. Tesamorelin reduced visceral fat and produced a modest reduction in liver fat compared with placebo. The researchers described the study as preliminary and called for more work to understand the long-term clinical meaning.
The 2026 meta-analysis also found an average reduction in liver fat across the included trials. This supports continued research, but it does not turn tesamorelin into an approved treatment for every cause of fatty liver disease. A finding can be real and useful while still remaining outside the medicine's approved purpose.
Does Tesamorelin Help Build Muscle?
The fairest answer is that some studies found changes in lean body mass and muscle measurements, but tesamorelin is not approved as a muscle-building drug.
In the two pivotal studies, mean lean body mass increased by a little over one kilogram after 26 weeks. An exploratory secondary analysis also reported increases in the area and density of several trunk muscles. That analysis included people with HIV and abdominal obesity, and the tesamorelin group was restricted to people who had already responded with a meaningful visceral-fat reduction.
Those limits are important. Lean body mass is not the same thing as new functional muscle. It includes water and other non-fat tissue, and a scan cannot tell us by itself whether someone became stronger or performed better. The exploratory muscle analysis was not a bodybuilding trial, and its authors said the long-term effects and practical meaning needed further study.
Using these findings to advertise tesamorelin for muscle gain in healthy people goes beyond the evidence.
Is Tesamorelin Growth Hormone?
No. Tesamorelin and growth hormone are different molecules that act at different points in the same pathway.
Natural GHRH is released by the hypothalamus and signals the pituitary. The pituitary then releases growth hormone. Tesamorelin imitates the first signal. It depends on the pituitary gland being able to respond.
| Molecule | Main role |
|---|---|
| Natural GHRH | A hypothalamic peptide that signals the pituitary to release growth hormone |
| Tesamorelin | A synthetic GHRH analogue that stimulates the same receptor pathway |
| Growth hormone | A separate pituitary hormone that acts on tissues and raises IGF-1 |
| IGF-1 | A growth factor produced mainly by the liver and other tissues in response to growth hormone |
Calling tesamorelin “growth hormone” skips a whole biological step and can lead to poor comparisons between products.
Does Tesamorelin Increase Testosterone?
Tesamorelin is not a testosterone medicine, and increasing testosterone is not its approved purpose.
The EGRIFTA clinical trials did not find a clinically significant change in luteinising hormone, or LH, one of the pituitary hormones involved in testosterone regulation. That does not prove that every individual's testosterone level will stay exactly the same, but it gives no basis for presenting tesamorelin as a testosterone booster.
Claims about testosterone, sexual performance or hormone replacement should be treated separately from the evidence for reducing visceral fat in HIV-associated lipodystrophy.
Is Tesamorelin a Steroid?
No. Tesamorelin is a peptide made from amino acids. Steroids have a different chemical structure based on four connected carbon rings.
The confusion usually comes from the word anabolic, which can describe tissue-building effects of many different biological signals. An anabolic effect does not make a molecule an anabolic steroid. Growth hormone, IGF-1, insulin and some amino-acid signals can all influence tissue growth without being steroids.
Tesamorelin also does not work through androgen receptors, which are central to the effects of testosterone and anabolic steroids.
Tesamorelin and Sermorelin: Are They the Same?
No. Tesamorelin and sermorelin are both synthetic analogues of GHRH, so they act on the same general receptor pathway, but they are not the same peptide.
Tesamorelin contains the full 44-amino-acid GHRH sequence with an added hexenoyl group. Sermorelin is based on a shorter part of the GHRH sequence. Their structures, evidence bases and finished products are different.
One should not be treated as a direct substitute for the other. Evidence from EGRIFTA trials belongs to tesamorelin products used in the studied population. It does not automatically establish the safety, purity or effectiveness of another GHRH analogue.
What did Health Canada's 2026 peptide warning find?
In November 2026, Health Canada reported that laboratory testing had found Sphingomonas aquatilis/melonis bacteria in one injectable peptide product seized from a Canadian retailer. The retailer's inventory also included products labelled tesamorelin. The agency did not say that every listed product or batch was contaminated.
This is evidence of a product-quality problem in an unauthorised supply chain, not a clinical trial of tesamorelin. Contamination of an injectable product can cause serious infection. A label stating 'for research use only' does not establish sterility or suitability for human use. The advisory does not imply that authorised medicines or regulated clinical-trial supplies were affected.
Is Tesamorelin Safe?
Tesamorelin is an approved prescription medicine with known benefits and important risks. “Approved” does not mean suitable for everyone, and there is no responsible yes-or-no safety answer without considering the person, indication, product and monitoring.
The current EGRIFTA WR label lists several situations in which the medicine must not be used. These include active cancer, pregnancy, known hypersensitivity and disruption of the hypothalamic-pituitary axis. A past cancer also requires careful medical assessment because tesamorelin increases growth hormone and IGF-1 signalling.
Important warnings include:
- Raised IGF-1: The long-term effects of sustained high IGF-1 are unknown, so the approved label calls for monitoring.
- Glucose intolerance or diabetes: Blood glucose can worsen, and people require assessment before and during treatment.
- Fluid retention: This can appear as swelling, joint pain, limb discomfort or carpal tunnel syndrome.
- Hypersensitivity: Rashes, itching, flushing, hives and other reactions have occurred.
- Injection-site reactions: Redness, itching, pain, irritation and bruising were reported in clinical trials.
- Acute critical illness: The label advises clinicians to consider stopping treatment in critically ill patients because of concerns associated with growth hormone signalling.
Commonly reported adverse effects include joint pain, muscle pain, pain in the arms or legs, peripheral swelling and reactions at the injection site.
Does Tesamorelin Cause Cancer?
It has not been established that tesamorelin causes cancer in humans. The concern is more specific than that.
Tesamorelin stimulates the release of growth hormone and raises IGF-1, both of which are growth signals. The prescribing information therefore says that people with active cancer must not use EGRIFTA WR. It also advises careful assessment for people with a history of cancer and discontinuation if there is evidence of recurrence.
The long-term effects of prolonged IGF-1 elevation are unknown. That uncertainty is one reason clinical monitoring matters. It is not evidence that every exposure causes cancer, but it is also not a risk that should be dismissed.
Does Approval Apply to Every Product Called Tesamorelin?
No. FDA approval applies to a specific finished medicine made to defined standards. It does not automatically extend to every vial, powder or online product carrying the name tesamorelin.
EGRIFTA WR and EGRIFTA SV are prescription products with different formulations. Their prescribing information states that they are not substitutable. Even two approved versions containing the same active molecule can have different strengths, preparation instructions and storage requirements.
The gap is greater for material sold as a research chemical. A label saying “tesamorelin” does not prove identity, purity, sterility, stability or clinical equivalence. Research-use material is not an approved medicine and should not be used in humans or animals.
Frequently Asked Questions
What is tesamorelin peptide?
Tesamorelin is a synthetic 44-amino-acid peptide based on human growth hormone-releasing hormone. It has an added hexenoyl group attached at the beginning of the amino-acid chain.
What does tesamorelin do?
Tesamorelin activates GHRH receptors in the pituitary gland. This increases pulsatile release of the body's own growth hormone and raises IGF-1. Its approved clinical use is to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
What is tesamorelin used for?
The approved EGRIFTA indication is the reduction of excess abdominal fat in adults with HIV and lipodystrophy. Tesamorelin does not treat HIV itself and is not approved for general weight loss, anti-ageing or bodybuilding.
Does tesamorelin work?
Randomised controlled trials found meaningful average reductions in visceral abdominal fat in adults with HIV-associated lipodystrophy. Average body weight changed very little, and the benefit began to reverse after treatment stopped.
How long does tesamorelin take to work?
The pivotal trials assessed body-composition outcomes at 26 weeks. That is a research timeframe, not a guaranteed personal result or a treatment recommendation.
Is tesamorelin safe?
It is an approved medicine with significant contraindications, warnings and monitoring requirements. Risks include high IGF-1, changes in glucose control, fluid retention, hypersensitivity and injection-site reactions. Suitability requires a qualified healthcare professional.
Does tesamorelin help build muscle?
Trials found modest average increases in lean body mass, and one exploratory analysis found changes in some muscle measurements. Tesamorelin is not approved for muscle building, and these findings do not prove a bodybuilding benefit in healthy people.
Does tesamorelin cause cancer?
A causal link has not been established in humans. Because tesamorelin increases growth hormone and IGF-1 signalling, the approved label prohibits its use with active cancer and calls for careful assessment in people with a cancer history.
Does tesamorelin increase testosterone?
Tesamorelin is not a testosterone therapy. Clinical trials did not find a clinically significant change in luteinising hormone, and there is no basis for describing tesamorelin as a testosterone booster.
Is tesamorelin a steroid?
No. Tesamorelin is an amino-acid peptide and GHRH analogue. Steroids have a different chemical structure and act through different receptor systems.
Is tesamorelin growth hormone?
No. Tesamorelin signals the pituitary gland to release endogenous growth hormone. Growth hormone is a separate molecule produced one step later in the pathway.
Is tesamorelin a weight-loss medicine?
No. The approved label says EGRIFTA WR is not indicated for weight-loss management and has a weight-neutral effect. It is used to reduce excess abdominal fat in a specific HIV-associated condition.
The Bottom Line
What is tesamorelin? It is a synthetic 44-amino-acid peptide that imitates growth hormone-releasing hormone. It acts on the pituitary gland, prompting the body to release more of its own growth hormone and increasing IGF-1.
Its strongest evidence is also its approved use: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The clinical trials showed that visceral fat can fall while overall body weight changes very little. They also showed that the effect begins to reverse when treatment stops.
Tesamorelin is not growth hormone, a steroid, a testosterone booster or a general weight-loss drug. Some research found increases in lean body mass and changes in muscle or liver fat, but those findings do not make it an approved bodybuilding or fatty-liver treatment.
The clearest way to judge a claim about tesamorelin is to ask three questions: Which population was studied? Which outcome was measured? Does the claim stay within the evidence and approved indication? That simple check separates a useful scientific finding from marketing that asks the molecule to prove too much.
See how Orentra reviews peptide research
Human, animal and laboratory findings are not treated as equivalent evidence. See how we select sources, assess studies, apply evidence labels and keep guides up to date.
Keep exploring the peptide knowledge base
Read the peptide fundamentals or return to the catalogue to browse other research guides.
Sources
The current DailyMed EGRIFTA WR label is the primary source for the approved indication, structure, clinical-trial results, contraindications and safety warnings. The remaining sources provide clinical-trial and review context.
US National Library of Medicine, DailyMed. Updated July 29, 2026. Current indication, structure, mechanism, clinical trials, contraindications and safety information.
Open source →Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionFalutz J, Potvin D, Mamputu JC, et al. Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-322.
Open source →Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationFalutz J, Allas S, Mamputu JC, et al. AIDS. 2008;22(14):1719-1728.
Open source →Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trialStanley TL, Feldpausch MN, Oh J, et al. JAMA. 2014;312(4):380-389.
Open source →The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIVAdrian S, Scherzinger A, Sanyal A, et al. Journal of Frailty & Aging. 2019;8(3):154-159.
Open source →Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trialsBadran AS, Helal A, Shata KS, Ayesh H. Obesity Research & Clinical Practice. 2026;20(1):2-12.
Open source →Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophySpooner LM, Olin JL. Annals of Pharmacotherapy. 2012;46(2):240-247.
Open source →Health Canada: unauthorised peptides and bacterial contamination, 12 November 2026Bacteria were found in one seized injectable peptide product; the retailer also stocked products labelled tesamorelin. The agency did not identify every stocked product as contaminated.
Open source →Last reviewed: 17 November 2026.